Lilly Bows To The Ftc
ELI LILLY'S $4 BILLION PURchase of a major drug benefits manager is likely to get a green light from trustbusters at the Federal Trade Commission after all--with strings. The company has agreed to FTC conditions meant to ensure that its acquisition of McKesson's PCS unit won't diminish competition: PCS will make its shopping list of drugs available to all drugmakers and will set up a "firewall" to prevent information on bids from rival drugmakers from flowing to Lilly, say sources close to the talks. Consumer advocates and trustbusters fear that drug benefits managers bought by pharmaceutical companies may favor their owners' products over those of rivals.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Smartphones Are Killing Americans, But Nobody’s Counting
- Why a Pub in the Middle of Nowhere Was Named the World’s Best Restaurant
- Gulf Coast Oil Spill May Be Largest Since 2010 BP Disaster
- Racist Outburst Prompts Faber’s Exit From Three Company Boards
- Airbus Snaps Up Bombardier Jet in New Challenge to Boeing